Catalent Inc (NYSE:CTLT) has reported Q2 FY22 sales of $1.22 billion, +34% Y/Y as reported, or 35% in constant currency, edging out analysts' average expectation of $1.15 billion.
- Adjusted EPS of $0.90, compared to $0.63 last year, surpassed the consensus of $0.83.
- Adjusted EBITDA was $310 million, or a margin of 25.4%, compared to $224 million (24.5%) a year ago.
- Biologics segment sales increased 57.9% (60% cc) to $638 million.
- Softgel and Oral Technologies segment revenues of $329 million were up 33.2% (36% cc).
- The Oral and Specialty Delivery segment's sales were $156 million, a decrease of -8.2% (-8% cc).
- Clinical Supply Services segment revenues improved 6.5% (7% cc) to $99 million.
- Related: FDA Concerns At Catalent Site Spurred Novo Nordisk's Wegovy Supply Woes: Report.
- Guidance: For FY22, Catalent expects revenue of $4.74 billion - $4.86 billion, versus the consensus of $4.71 billion, and higher than prior guidance of $4.62 billion - $4.82 billion.
- It expects adjusted EBITDA of $1.25 billion - $1.30 billion, compared to $1. 225 billion - $1.295 billion expected earlier.
- The Company forecasts adjusted net income of $650 million - $700 million, better than $630 million - $695 million anticipated earlier.
- Price Action: CTLT shares closed at $103.93 on Monday.
